BPTES

Name: BPTES
Brand: MedChemExpress
SKU: HY-12683
Rating: 5.0 (61 reviews)

Cat. No.: HY-12683 Pureza: 98.04%: Ficha de datos
COA

SDS
Instrucciones de manejo
FAQs
Technical Support

BPTES is an allosteric and selective glutaminase inhibitor with an IC₅₀ of 0.16 μM.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 314045-39-1

Tamaño	Stock	Cantidad

Muestra gratis (0.1 - 0.2 mg)	Solicite ahora
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	En stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	En stock	Estimated Time of Arrival: December 31
Solid
5 mg	En stock	Estimated Time of Arrival: December 31
10 mg	En stock	Estimated Time of Arrival: December 31
25 mg	En stock	Estimated Time of Arrival: December 31
50 mg	En stock	Estimated Time of Arrival: December 31
100 mg	En stock	Estimated Time of Arrival: December 31
200 mg	En stock	Estimated Time of Arrival: December 31
500 mg	Obtener un presupuesto
1 g	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 61 publication(s) in Google Scholar

Other Forms of BPTES:

BPTES (Standard) Obtener un presupuesto

61 Publications Citing Use of MCE BPTES

2D/3D Cell Culture and Differentiation

Flow Cytometry

: BPTES purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 15;16(1):4502. [Abstract]; BPTES (3 μM, 3 days) had no effect on ACLY expression and H3K27 and H3K9 acetylation in patient CD4+ T cells.

: BPTES purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 15;16(1):4502. [Abstract]; BPTES (3 μM, 48 h) did not reverse the increase in IFNγ, T-bet, IL-17A, and RORγt expression in Tigit^−/−CD4⁺ T cells cultured under Th1- or Th17-polarizing conditions.

: BPTES purchased from MedChemExpress. Usage Cited in: Mater Today Bio. 2025 Feb 25:31:101608.; BPTES (0-160μM, 24 h (left) and 48 h (right)) combined with RT (4Gy) inhibited cell growth in HepG2 cells.

: BPTES purchased from MedChemExpress. Usage Cited in: Cell Metab. 2022 Nov 1;34(11):1843-1859.e11. [Abstract]; BPTES treatment (3 μM, 55 min) reduced the maximal and spare respiratory capacity of Kcnj2^f/f tumor-associated macrophages.

: BPTES purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2020 Aug;85:106664. [Abstract]; BPTES/CB839 could efficiently and specifically inhibit the NLRP1b inflammsome signaling pathway in J774A.1 cells. The cell lysate is analyzed by immunoblotting using anti-Caspase-1 and anti-GAPDH antibodies.

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Actividad biológica
Protocolo
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

BPTES is an allosteric and selective glutaminase inhibitor with an IC₅₀ of 0.16 μM.

IC₅₀ & Target

Glutaminase^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.42 μM Compound: BPTES	Antiproliferative activity against human A549 cells after 5 days by EZMTT reagent-based assay Antiproliferative activity against human A549 cells after 5 days by EZMTT reagent-based assay	[PMID: 30543285]
A549	IC₅₀	276 nM Compound: 2, BPTES	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by celltiter-fluor assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by celltiter-fluor assay	[PMID: 33118821]
A549	IC₅₀	49 μM Compound: BPTES	Antiproliferative activity against human A549 cells assessed as reduction in cell viability Antiproliferative activity against human A549 cells assessed as reduction in cell viability	[PMID: 36055003]
ASPC1	IC₅₀	10.2 μM Compound: BPTES	Growth inhibition of human Aspc-1 cells after 72 hrs by MTS assay Growth inhibition of human Aspc-1 cells after 72 hrs by MTS assay	[PMID: 28609101]
CAKI-1	IC₅₀	1.16 μM Compound: BPTES	Antiproliferative activity against human Caki1 cells after 5 days by EZMTT reagent-based assay Antiproliferative activity against human Caki1 cells after 5 days by EZMTT reagent-based assay	[PMID: 30543285]
H22	IC₅₀	> 10 μM Compound: BPTES	Antiproliferative activity against mouse H22 cells after 5 days by EZMTT reagent-based assay Antiproliferative activity against mouse H22 cells after 5 days by EZMTT reagent-based assay	[PMID: 30543285]
HCC827	IC₅₀	42.4 μM Compound: BPTES	Cytotoxicity against human erlotinib-resistant HCC827 cells assessed as growth inhibition after 48 hrs by CCK8 assay Cytotoxicity against human erlotinib-resistant HCC827 cells assessed as growth inhibition after 48 hrs by CCK8 assay	[PMID: 28174105]
HCT-116	IC₅₀	0.54 μM Compound: BPTES	Antiproliferative activity against human HCT116 cells after 5 days by EZMTT reagent-based assay Antiproliferative activity against human HCT116 cells after 5 days by EZMTT reagent-based assay	[PMID: 30543285]
HCT-116	IC₅₀	1.02 μM Compound: BPTES	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31603674]
HCT-116	IC₅₀	3.91 μM Compound: BPTES; I-3	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33792311]
HCT-116	IC₅₀	44 μM Compound: BPTES	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability	[PMID: 36055003]
HT-1080	IC₅₀	47.72 μM Compound: BPTES	Cytotoxicity against human HT1080 cells assessed as growth inhibition after 48 hrs by CCK8 assay Cytotoxicity against human HT1080 cells assessed as growth inhibition after 48 hrs by CCK8 assay	[PMID: 28174105]
MDA-MB-231	IC₅₀	2610 nM Compound: BPTES	Cytotoxicity against human MDA-MB-231 cells measured on 6th day by hemocytometry Cytotoxicity against human MDA-MB-231 cells measured on 6th day by hemocytometry	[PMID: 26988803]
MDA-MB-231	IC₅₀	6.8 μM Compound: BPTES	Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTS assay Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTS assay	[PMID: 28609101]
MDA-MB-231	IC₅₀	9.08 μM Compound: BPTES	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 33176943]
MDA-MB-436	IC₅₀	2.4 μM Compound: BPTES	Antiproliferative activity against human MDA-MB-436 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-436 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31603674]
MDA-MB-436	IC₅₀	5.08 μM Compound: BPTES; I-3	Antiproliferative activity against human MDA-MB-436 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-436 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33792311]
NCI-H1703	GI₅₀	1.3 μM Compound: 3; BPTES	Antiproliferative activity against human NCI-H1703 cells assessed as reduction in cell growth after 5 days by SYTOX green staining-based assay Antiproliferative activity against human NCI-H1703 cells assessed as reduction in cell growth after 5 days by SYTOX green staining-based assay	[PMID: 31199640]
SW1990	IC₅₀	35.33 μM Compound: 1; BPTES	Antiproliferative activity against human SW1990 cells assessed as reduction in cell viability measured after 72 hrs by CCK-8 assay Antiproliferative activity against human SW1990 cells assessed as reduction in cell viability measured after 72 hrs by CCK-8 assay	[PMID: 36996714]

In Vitro

BPTES (10 μM) exhibits inhibition of PDAC cell proliferation^[1]. BPTES preferentially slows growth of mutant IDH1 cells without inducing apoptosis. BPTES (10 μM) reduces glutaminase activity in both WT and mutant IDH1 expressing cells, diminishes glutamate and α-KG levels, and increases glycolytic intermediates while leaving total 2-HG levels unaffected^[2]. BPTES (10 μM) shows a clear synergistic anti-cancer effect with 10 μM of 5-FU in A549 and EKVX cell lines, and results in a growth reduction response not only in EKVX and A549 but also in most of the NSCLC cell lines^[3]. BPTES (10 μM) effectively reduces the levels of the metabolites of the TCA cycle, with no changes in the levels of metabolites in glycolysis and the pentose phosphate pathway. BPTES treatment reduces about 30% ATP production under normoxia, and an additional 10% reduction of ATP production is observed under hypoxia in EKVX^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BPTES-NPs (BPTES nanoparticles, 1.2 mg BPTES in 100 μL nanoparticles, i.v.) significantly attenuates tumor growth in the patient-derived pancreatic orthotopic tumor model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Peso molecular

524.68

Fòrmula

C₂₄H₂₄N₆O₂S₃

No. CAS

314045-39-1

Appearance

Solid

Color

White to off-white

SMILES

O=C(NC1=NN=C(CCSCCC2=NN=C(NC(CC3=CC=CC=C3)=O)S2)S1)CC4=CC=CC=C4

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvente y solubilidad

In Vitro:

DMSO : 25 mg/mL (47.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9059 mL	9.5296 mL	19.0592 mL
5 mM	0.3812 mL	1.9059 mL	3.8118 mL
10 mM	0.1906 mL	0.9530 mL	1.9059 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (4.76 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (3.96 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 3

Add each solvent one by one: 2% DMSO 40% PEG300 5% Tween-80 53% Saline
Solubility: 2 mg/mL (3.81 mM); Suspended solution; Need ultrasonic
Protocol 4

Add each solvent one by one: 5% DMSO 95% Corn Oil
Solubility: ≥ 0.62 mg/mL (1.18 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Pureza y Documentación

Purity: 98.75%

Select Batch:

Ficha de datos (277 KB) SDS (393 KB)

COA (246 KB) HNMR (387 KB) RP-HPLC (260 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Elgogary A, et al. Combination therapy with BPTES nanoparticles and targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):E5328-36. [Content Brief]

[2]. Meghan J. Seltzer, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010 Nov 15; 70(22): 8981-8987. [Content Brief]

[3]. Lee JS, et al. Glutaminase 1 inhibition reduces thymidine synthesis in NSCLC. Biochem Biophys Res Commun. 2016 Aug 26;477(3):374-82 [Content Brief]

[4]. Lee JS, et al. Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC. Cell Death Dis. 2016 Dec 8;7(12):e2511. [Content Brief]

Ensayo celular ^[2]	Cells are plated at a density of 500 cells/well in a 96-well black clear bottom plate. At 24 hrs, media is changed to the appropriate media (DMEM with 4.5 g/L, 1.5 g/L or 0.1 g/L glucose, 10% FBS, and 4 mM glutamine). 48 hours after plating, compounds or DMSO are added. Media and alamarBlue is added to a volume of 200 µL in each well. Fluorescence is measured at 48 hrs or 72 hrs (EGCG) using a Victor3 plate-reader. MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.
Administraciòn de animales ^[1]	Four-week-old female Foxn1nuathymic nude mice are used for the assay. Freshly resected pancreatic tumor samples obtained from patients at the time of surgery are propagated from mouse to mouse as a live tumor bank. Once a tumor volume of 50 mm³ is reached (4 wk postimplantation), mice are treated with 12.5 mg/kg BPTES by intraperitoneal injection, 200 mg/kg CB-839 twice per d by oral gavage, 54 mg/kg BPTES-NPs (1.2 mg BPTES in 100 µL nanoparticles per mouse) by intravenous injection, blank-NPs (100 µL per mouse) by intravenous injection, 25 mg/kg LY 188011 intraperitoneally, or a combination of BPTES-NPs with LY 188011. BPTES-NPs are injected once every 3 d for a total of six injections over 16 d. MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.
Referencias	[1]. Elgogary A, et al. Combination therapy with BPTES nanoparticles and targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):E5328-36. [Content Brief] [2]. Meghan J. Seltzer, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010 Nov 15; 70(22): 8981-8987. [Content Brief] [3]. Lee JS, et al. Glutaminase 1 inhibition reduces thymidine synthesis in NSCLC. Biochem Biophys Res Commun. 2016 Aug 26;477(3):374-82 [Content Brief] [4]. Lee JS, et al. Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC. Cell Death Dis. 2016 Dec 8;7(12):e2511. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9059 mL	9.5296 mL	19.0592 mL	47.6481 mL
	5 mM	0.3812 mL	1.9059 mL	3.8118 mL	9.5296 mL
	10 mM	0.1906 mL	0.9530 mL	1.9059 mL	4.7648 mL
	15 mM	0.1271 mL	0.6353 mL	1.2706 mL	3.1765 mL
	20 mM	0.0953 mL	0.4765 mL	0.9530 mL	2.3824 mL
	25 mM	0.0762 mL	0.3812 mL	0.7624 mL	1.9059 mL
	30 mM	0.0635 mL	0.3177 mL	0.6353 mL	1.5883 mL
	40 mM	0.0476 mL	0.2382 mL	0.4765 mL	1.1912 mL

BPTES Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BPTES314045-39-1GlutaminaseInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Nombre del producto			Requested Quantity *
Nombre del solicitante *			Saludo
Direcciòn del E-mail *			Número de teléfono *
Department			Nombre de la Organizaciòn *
City			Provincia
Country or Region *
Observaciones

Nombre del producto			Lot #
Nombre del solicitante *			Direcciòn del E-mail *
Número de teléfono			Department *
Nombre de la Organizaciòn *			Country or Region *
Observaciones

Name
E-mail *

	Sorry, but the email address you supplied was invalid.

BPTES

Revisión del cliente

Other Forms of BPTES:

BPTES Related Antibodies

61 Publications Citing Use of MCE BPTES

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Actividad biológica

Protocolo

Pureza y Documentación

Referencias

Revisión del cliente

BPTES Related Antibodies

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

BPTES Related Classifications

Keywords:

Productos vistos recientemente:

Revisión del cliente

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report